NCT06069947Not yet recruiting
SALT for Liver Cirrhosis With HCC
Sequential Adult Left Lateral Lobe Liver Transplantation (SALT) in Patients With Liver Cirrhosis With Hepatocellular Carcinoma(HCC): a Single-center, Prospective, Single-arm Study
Source: ClinicalTrials.gov · Last updated 6 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
HCC is the third leading cause of cancer deaths worldwide. Although surgical treatment may be effective in patients with HCC, the five-year survival rate is only 50-70%. Moreover, due to the lack of early diagnostic marker, most patients with HCC are often diagnosed in an advanced stage with poor prognosis. Therefore, there is an urgent need to further understand the possible aetiological factors and surgical treatment methods to improve the prognosis of patients with HCC. Liver transplantation is an ideal choice for patients with liver cirrhosis with HCC, which can significantly improve the postoperative survival rate. But the most serious problem facing such patients is the shortage of donor livers. In 2015, Norwegian scholars proposed a new surgical method, that is, resection and partial liver segment (2-3 segment) transplantation combined with delayed total hepatectomy can greatly alleviate the shortage of liver donors in the above-mentioned patients. Based on the experience of clinical operation, our center proposes and designs a clinical study of sequential adult left lateral lobe liver transplantation (SALT) for the treatment of patients with liver cirrhosis with HCC. On the basis of RAPID, the safety and efficacy of sequential adult left lateral lobe liver transplantation were evaluated for the above patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 22 Sept 2023
- Start date
- 20 Oct 2023
- Primary completion date
- 30 Mar 2027
- Lead sponsor
- RenJi Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06069947
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 20 Oct 2023 to the primary completion date, 30 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Combined with pulmonary hypertension(high-risk or middle-risk, WHO grade: III-IV);
- Cardiopulmonary disease or severe infection or Cerebral Vascular Disease that cannot be corrected, with high surgical risk, that makes liver transplantation impossible;
- Psychological or social conditions may interfere with the patient's participation in the study or evaluation of the study results;
Other
- Combined with the main portal vein tumor thrombus, the main vena cava tumor thrombus and common bile duct tumor thrombus;
- Combined with severe hepatic encephalopathy ;
- Special types of anatomical variations(such as portal vein classification: type III and type IV, etc. );
- Extrahepatic tumor burden;
- Other reasons that the researchers think are not suitable for participation.
Who the study is looking for
- Age 18-75;
- Child-Pugh A-B ;
- liver cirrhosis with Heoatocellular Carcinoma (HCC) with Hepatitis B virus infection 4. Patients with Heoatocellular Carcinoma (HCC) meets the "up to seven" criteria: the sum of tumour size and tumour numbers does not exceed 7;
- 5\. Performance Status 0-1; 6. Sign the informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.